The MFDS has expanded the scope of the impurity investigation to ARB drugs as a whole. However, Telmisartan·Azilsartan·Eprosartan were excluded from the list of additional investigations.

The pharmaceutical industry understands that Telmisartan was excluded from the impurity survey because it does not have a tetrazole ring.

The MFDS said on the 23rd, an official letter was sent to analyze and evaluate the possibility of impurities occurring in Olmesartan, Fimasartan, and Candesartan. The company that owns the drug in question shall analyze and submit the possibility of 'AZBT/Azido Methyl Bipheny Tetrazole' by the 22nd of next month.

The scope of impurity investigation has